Editorial · Worth a closer look
6 flagged
Sus.
Patterns in this bill where the public record raises questions worth asking — concentrated procurement, lobby-to-contract overlaps, off-scope flows, and repeat sponsor-recipient relationships. Each finding is a fact, not a verdict.
The shape of it
Concentration
$157B
Top-5 defense contractors (~$150B/yr) + ~$7B in earmarks concentrated in three civilian divisions.
2 findings
Lobby Overlap
$62B
Lockheed Martin's annual DoD contracts compared to its ~$15M annual lobbying spend.
1 finding
Off-Scope
$5.3B
Defense bill money flowing abroad as security cooperation — Ukraine, Taiwan, Baltics, NATO.
1 finding
Patterns
$3.3B
Israel FMF locked in through a 10-year bilateral MOU running 2019-2028.
1 finding
Five companies capture ~$150B per year — nearly 1 of every 5 Defense dollars
~$150B
Top-5 prime contractor total (annual)
~18%
of Defense's $839B FY26 total
5
Lockheed, RTX, GD, Northrop, Boeing
Lockheed Martin Corporation alone receives roughly $62B per year in DoD prime contracts — more than the entire CJS bill in HR 6938. The top five defense primes (Lockheed, RTX/Raytheon, General Dynamics, Northrop Grumman, Boeing Defense) collectively absorb about $150B annually. The same five names lead the procurement leaderboard every year.
Why it mattersDefense contracting is genuinely specialized — you can't switch jet manufacturers overnight. But when 20% of the largest discretionary category goes to five corporations year after year, the political incentives align: those companies have outsized lobbying power, and their employment footprints cover key Congressional districts. Cost overruns, schedule slips, and program failures rarely result in reassignment.
Lockheed Martin spent $15M lobbying Congress, gets $62B in this bill
$62B
DoD contracts (annual, illustrative)
~$15M
Lockheed federal lobbying, 2025
4,100×
contract-to-lobby ratio
Lockheed Martin Corporation's Senate lobbying disclosures filed each quarter list 'defense appropriations' as a specific lobbying priority. The company's products span F-35, Sikorsky helicopters, missile defense, satellites, and the Trident missile system — most of which are explicitly funded in this bill. Lockheed also operates the parent UEI hierarchy that includes Lockheed Martin Space (separately ranked #9 in our recipient leaderboard for HR 6938).
Why it mattersLobbying doesn't prove influence, but the public-record disclosure links the spending to specific appropriations bills. The 4,100× contract-to-lobby ratio is a measure of how leveraged this kind of access becomes — every $1 of lobbying spend correlates with $4,100 in federal contracts, which is well above the average for federal contractors.
$5.3B for foreign militaries is inside a 'Defense' bill, not foreign aid
$5.3B
Total security cooperation (foreign-flowing)
$1B
Taiwan Security Cooperation Initiative
$400M
Ukraine security cooperation (baseline)
$5.3 billion of HR 7148's Defense division flows abroad as 'security cooperation' — military training, equipment grants, and joint exercises with allies. The Ukraine portion ($400M baseline, separate from emergency supplemental aid) and Taiwan portion ($1B for TSCI) are funded under the same authorities that pay U.S. servicemembers. Citizens reading the Defense topline see '$839 billion for our troops' — most don't realize a chunk goes to foreign militaries.
Why it mattersThere are real strategic reasons to fund allied militaries through Defense rather than State — speed of execution, military-to-military relationships, equipment interoperability. But the budget categorization obscures what's actually happening. When 'Defense' includes 'paying for the Ukrainian military,' the framing matters for public understanding.
FY26 earmarks tripled — HR 7148 carries 5x more CPF dollars than HR 6938
~$7B
Total CPF in HR 7148 (illustrative)
~3,000
CPF entries across THUD, LHHS, FSGG
5x
vs HR 6938's $1.4B / 612 entries
THUD division alone carries roughly $3.6B in Community Project Funding per the conferenced bill summary — more than the total earmarks across all three of HR 6938's subcommittees combined. Add Labor-HHS-Education (~$3B, including $2B for 800+ higher-education projects) and FSGG (~$400M), and HR 7148 is the largest single source of earmarked spending in this FY26 cycle. Defense and National Security-State don't permit CPF, so this is concentrated in the civilian-domestic divisions.
Why it mattersEarmarks aren't inherently corrupt — they let Members fund specific community projects in their districts. But the scale of CPF in any one bill is a useful gauge of how 'member-directed' that bill is. HR 7148's $7B compared to HR 6938's $1.4B reflects which subcommittees historically have heavy earmark traditions (T-HUD always tops the list) and which don't (Defense, foreign affairs).
Israel gets the same $3.3B in foreign military financing it has gotten every year since 2019
10 years
U.S.-Israel MOU 2019-2028
$38B
Total MOU commitment over decade
The U.S.-Israel Memorandum of Understanding signed in 2016 (effective FY2019-2028) sets Israel's FMF at $3.3 billion per year plus $500M annually for missile defense cooperation. Congress has appropriated this amount every fiscal year since the MOU took effect, regardless of which party controls either chamber. Israel is the largest cumulative FMF recipient in U.S. history.
Why it mattersWhether this is good policy is a political debate. But the pattern itself — guaranteed flat appropriation over a decade, baked into a bilateral agreement — is structurally unusual. Most foreign aid is reauthorized and debated annually. FMF for Israel is closer to an entitlement on the books than a discretionary line item.
Moderna's $1.75B mRNA contract dwarfs the BARDA mRNA program HHS terminated
$1.75B
Moderna's active BARDA mRNA-licensure contract (FY24)
~$500M
BARDA mRNA program HHS wound down (Aug 2025)
22
mRNA investments terminated or de-scoped
In August 2025, HHS (under Secretary RFK Jr.) announced a coordinated wind-down of BARDA's mRNA vaccine development portfolio — terminating or de-scoping 22 investments totaling roughly $500M, with Pfizer and Sanofi proposals rejected, CSL Seqirus/ModeX/Luminary Labs reduced, and Emory/Tiba Biotech terminated. Yet Moderna's single $1.75B BARDA mRNA-licensure contract (FY24, restructured during the wind-down rather than canceled) remains active — roughly 3.5x the size of the entire program HHS curtailed. Sourced from HHS's own press release, the Citizen.org BARDA funding tracker, and USAspending contract records.
Why it mattersAn across-the-board program decision that terminates two dozen mRNA investments while leaving the single largest one intact is exactly the kind of asymmetry worth scrutiny. Members of Congress sitting on House Energy & Commerce or Senate HELP — the committees with health jurisdiction — who hold Moderna (MRNA) should be reviewed in light of it. The conflict-flagging pipeline now surfaces MRNA trades for those Members.
Findings here describe public-record patterns. They are not allegations of wrongdoing. Lobbying spend, donor relationships, and procurement concentration are all legal and disclosed — surfacing them is what transparency tools are for.